# US 9,518,989 B2 · Composition and method for diagnosis and immunotherapy of lung cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,518,989 B2
- Document ID: US9518989B2
- Status: Granted
- Kind: B2
- Application number: 14/178,407
- Filed: 2014-02-12
- Published: 2015-02-26
- Granted: 2016-12-13
- Earliest claimed: 2013-02-12
- Assignees: Texas Tech University System
- Applicants: Texas Tech University System
- Inventors: Maurizio Chiriva-Internati
- Web page: https://patentgrep.com/patent/US9518989B2

## CPC

- G01N 33/57585: {involving compounds identifiable in body fluids}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/42: Cancer antigens
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 35/00: Antineoplastic agents
- C07K 14/47: from mammals
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 16/3023: {Lung}
- C12N 9/12: transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N 33/5752: of the lungs
- A61K 35/15: Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells (presenting a specific antigen A61K39/00; therapeutic combinations of antibodies, or fragments thereof, and blood-derived cells A61K39/00)
- A61K 2039/5154: {Antigen presenting cells [APCs], e.g. dendritic cells or macrophages}
- A61K 2039/572: {cytotoxic response}
- G01N 2333/47: Assays involving proteins of known structure or function as defined in the subgroups
- G01N 2333/705: Assays involving receptors, cell surface antigens or cell surface determinants
- G01N 2333/912: transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention includes compositions and methods for the diagnosis and treatment of lung cancer with a recombinant tumor-associated antigen loaded antigen presenting cell that generates a cytotoxic T lymphocyte specific immune response to at least one of SP17, AKAP-4, or PTTG1 expressed by one or more lung cancer cells.

## Claims

### Claim 1

A composition for the treatment of lung cancer comprising:
an isolated antigen presenting cell that has been loaded with an SP17 tumor associated antigen, an AKAP-4 antigen, and a PTTG1 antigen, wherein the antigen presenting cells activates cytotoxic T lymphocytes against the SP17 tumor associated antigen, the AKAP-4 antigen, and the PTTG1 antigen are expressed in the antigen presenting cells for presentation by Class I MHC, and the cytotoxic T lymphocytes kill one or more lung cancer cells that present one or more of the antigens.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the antigen presenting cell is a dendritic cell.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the antigen presenting cell is an autologous dendritic cell.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the antigen presenting cell is modified to express a nucleotide sequence that codes for a recombinant SP17 tumor-associated antigen and the SP17 tumor-associated antigen is presented via Class I WIC.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the antigen presenting cell is modified to express a nucleotide sequence that codes for a recombinant AKAP-4 antigen and the AKAP-4 antigen is presented via Class I MHC.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the antigen presenting cell is modified to express a nucleotide sequence that codes for a recombinant PTTG1 antigen and the PTTG1 antigen is presented via Class I MHC.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the cytotoxic T lymphocytes have a Th-1 polarization.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the lung cancer is a non-small cell lung carcinoma.